Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company arGentis Pharmaceuticals LLC
DescriptionOligopeptide derived from human CII sequence
Molecular Target T cell receptor (TCR)
Mechanism of ActionImmune modulation
Therapeutic ModalityPeptide
Latest Stage of DevelopmentPhase I
Standard IndicationRheumatoid arthritis (RA)
Indication DetailsTreat Rheumatoid arthritis (RA)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today